Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Shu-Chen Lu, Michelle Chen, Larissa Atangan, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 5, pp. 100263-100263
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 124
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 101
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 85
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 79
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 70
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan, et al.
Nature Metabolism (2024) Vol. 6, Iss. 2, pp. 290-303
Open Access | Times Cited: 61
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 56
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 26
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 1
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 5, pp. 587-597
Open Access | Times Cited: 30
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 22
Beneath the surface: endosomal GPCR signaling
Emmanuel Flores-Espinoza, A. Thomsen
Trends in Biochemical Sciences (2024) Vol. 49, Iss. 6, pp. 520-531
Closed Access | Times Cited: 14
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 12
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 7
Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Lijing Wang
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1547-1559
Open Access | Times Cited: 31
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Samrin Kagdi, Sulayman A. Lyons, Jacqueline L. Beaudry
Journal of Endocrinology (2024) Vol. 261, Iss. 3
Open Access | Times Cited: 6
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Aaron Novikoff, Timo D. Müller
Physiology (2024) Vol. 39, Iss. 3, pp. 142-156
Closed Access | Times Cited: 5
The antiemetic actions of GIP receptor agonism
Tito Borner, Bart C. De Jonghe, Matthew R. Hayes
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 4, pp. E528-E536
Closed Access | Times Cited: 5
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Bin Yang, Vasily M. Gelfanov, Kimberley El, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101638-101638
Open Access | Times Cited: 25
Endogenous cell membrane interactome mapping for the GLP-1 receptor in different cell types
Ting Dang, Jie Yu, Zhihe Cao, et al.
Nature Chemical Biology (2024)
Closed Access | Times Cited: 4
Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose–High-Lipid Conditions: A Comparative Study
Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 421-421
Open Access
The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
Jonathan D. Douros, Jonathan N. Flak, Patrick J. Knerr
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Obesity-driven hunger: From pathophysiology to intervention
Ahmad Khusairi Azemi, Yahkub Babatunde Mutalub, Monsurat Abdulwahab, et al.
Obesity Medicine (2025), pp. 100588-100588
Closed Access
Effects of early-life F-53B exposure on thyroid function in juvenile rats: the role of the cAMP signaling pathway
Shen-Pan Li, Zhao Wen-hui, Jing Zhang, et al.
Journal of Hazardous Materials (2025), pp. 137751-137751
Closed Access
Page 1 - Next Page

Scroll to top